{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:44:09Z","timestamp":1791607449502,"version":"4.3.4"},"reference-count":179,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2472,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1093\/annonc\/mds643","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T01:42:00Z","timestamp":1361410920000},"page":"857-877","source":"Crossref","is-referenced-by-count":267,"title":["ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Iannitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wotherspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds643_bb0010","series-title":"Lyon","article-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mds643_bb0015","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood-2002-07-2216","article-title":"Splenic marginal zone lymphoma","volume":"101","author":"Franco","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds643_bb0025","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience","volume":"24","author":"Raderer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed","volume":"95","author":"Thieblemont","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0035","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0040","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/gut.52.11.1656","article-title":"Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma","volume":"52","author":"Copie-Bergman","year":"2003","journal-title":"Gut"},{"key":"10.1093\/annonc\/mds643_bb0045","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0050","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/gut.2006.096420","article-title":"Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series","volume":"56","author":"Fischbach","year":"2007","journal-title":"Gut"},{"key":"10.1093\/annonc\/mds643_bb0055","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0060","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC)","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0065","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mds643_bb0075","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients","volume":"120","author":"Parry-Jones","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds643_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2559.2005.02309.x","article-title":"A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases","volume":"48","author":"Traverse-Glehen","year":"2006","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mds643_bb0090","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0095","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/00000478-200306000-00006","article-title":"Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases","volume":"27","author":"Camacho","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mds643_bb0100","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0105","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0110","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.1999.17.8.2486","article-title":"Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project","volume":"17","author":"Nathwani","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Arcaini","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0120","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","article-title":"Progression to large B-cell lymphoma in splenic marginal zone lymphoma\u2014a description of a series of 12 cases","volume":"25","author":"Camacho","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mds643_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2008.07301.x","article-title":"High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis","volume":"143","author":"Dungarwalla","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds643_bb0135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2401710","article-title":"Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes","volume":"14","author":"Lefrere","year":"2000","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds643_bb0140","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/annonc\/mdp395","article-title":"Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)","volume":"21","author":"Cervetti","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds643_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mds643_bb0155","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds643_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"11","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds643_bb0165","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2004.08.011","article-title":"Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis","volume":"41","author":"Saadoun","year":"2004","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mds643_bb0170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds643_bb0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2559.2008.03060.x","article-title":"Mantle cell lymphoma with aberrant expression of CD10","volume":"53","author":"Zanetto","year":"2008","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mds643_bb0180","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds643_bb0185","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds643_bb0190","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2009.008474","article-title":"Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma","volume":"94","author":"Dictor","year":"2009","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds643_bb0195","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0200","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0205","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2010-01-263806","article-title":"Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling","volume":"116","author":"Hartmann","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0215","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1093\/annonc\/mds643_bb0220","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.semcancer.2011.09.007","article-title":"The complex landscape of genetic alterations in mantle cell lymphoma","volume":"21","author":"Royo","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1093\/annonc\/mds643_bb0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.1093\/annonc\/mds643_bb0230","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2014a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"De Jong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0235","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2006.08.7999","article-title":"Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors","volume":"25","author":"Kienle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0240","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2007.12.0410","article-title":"Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue","volume":"26","author":"Hartmann","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0245","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus","volume":"65","author":"Hernandez","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds643_bb0250","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mds643_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0260","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0265","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds643_bb0270","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds643_bb0275","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","article-title":"Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book","author":"Dreyling","year":"2009","journal-title":"Hematology"},{"key":"10.1093\/annonc\/mds643_bb0280","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0285","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0290","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0295","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0300","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0305","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0310","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds643_bb0315","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantlecell lymphoma: a population-based clinical study","volume":"14","author":"Velders","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0320","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2006.05970.x","article-title":"Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index","volume":"133","author":"M\u00f8ller","year":"2006","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0330","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mds643_bb0335","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood-2008-05-155507","article-title":"Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mds643_bb0340","article-title":"Mantle Cell Lymphoma International Prognostic Score is valid and confirmed in unselected cohort of patients treated in rituximab era","volume":"112","author":"Salek","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1093\/annonc\/mds643_bb0345","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428190903186494","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1093\/annonc\/mds643_bb0350","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3324\/haematol.2009.021113","article-title":"Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting","volume":"95","author":"van de Schans","year":"2010","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mds643_bb0355","article-title":"Retrospective analysis of 206 mantle cell lymphoma patients at diagnosis: Mantle Cell International Prognostic Index (MIPI) is a good predictor of death event in patients treated either with rituximab-chemotherapy or rituximab-high-dose-chemotherapy","volume":"116","author":"Chiappella","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1093\/annonc\/mds643_bb0360","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma International Prognostic Index but not pretransplantation induction regimen predicts surviva for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0365","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mds643_bb0370","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0375","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0380","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after highdose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0385","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression\u2014free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mds643_bb0390","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds643_bb0395","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0400","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds643_bb0405","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0410","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0415","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3324\/haematol.2010.025627","article-title":"Front-line treatment of mantle cell lymphoma","volume":"95","author":"Geisler","year":"2010","journal-title":"Haematol"},{"key":"10.1093\/annonc\/mds643_bb0420","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.seminhematol.2011.03.008","article-title":"Treatment of elderly patients with mantle cell lymphoma","volume":"48","author":"Kluin-Nelemans","year":"2011","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1093\/annonc\/mds643_bb0425","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0430","first-page":"CD003805","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1093\/annonc\/mds643_bb0435","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1093\/annonc\/mds643_bb0440","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"NEJM"},{"key":"10.1093\/annonc\/mds643_bb0445","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0450","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mds643_bb0455","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0460","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1093\/annonc\/mds643_bb0465","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1093\/annonc\/mds643_bb0470","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0475","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2010.01515.x","article-title":"Therapeutic concepts in mantle cell lymphoma","volume":"85","author":"Rodriguez","year":"2010","journal-title":"Eur J Hematol"},{"issue":"1","key":"10.1093\/annonc\/mds643_bb0480","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: the promise of new treatment options","volume":"80","author":"Goy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1093\/annonc\/mds643_bb0485","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.seminhematol.2011.06.002","article-title":"Treatment of younger patients with mantle cell lymphoma","volume":"48","author":"Harel","year":"2011","journal-title":"Sem Hematol"},{"key":"10.1093\/annonc\/mds643_bb0490","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0495","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.965.965","article-title":"R-CHOP\/R-DHAP Compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network","volume":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mds643_bb0500","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","article-title":"Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Jantunen","year":"2012","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mds643_bb0505","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0510","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.688.688","article-title":"Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the lymphoma working party of the EBMT","volume":"116","author":"Rubio","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mds643_bb0515","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0520","author":"Wang","year":"2011","journal-title":"The Bruton's kinas inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial"},{"issue":"3","key":"10.1093\/annonc\/mds643_bb0525","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds643_bb0530","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphomas: a phase II study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds643_bb0535","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"JCO"},{"key":"10.1093\/annonc\/mds643_bb0540","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0545","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiple relapsed and refractory mantle cell lymphoma\u2014long term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds643_bb0550","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma an mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"JCO"},{"key":"10.1093\/annonc\/mds643_bb0555","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non Hodgkin lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0560","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1083-8791(01)70016-X","article-title":"Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma","volume":"7","author":"Berdeja","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0565","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0570","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","article-title":"Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0575","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0580","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0585","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.20646","article-title":"Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"81","author":"Laudi","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mds643_bb0590","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10428190400015022","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma\u2014does it deserve a better look?","volume":"46","author":"Rifkind","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds643_bb0595","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0600","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0605","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British society for blood and marrow transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mds643_bb0610","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds643_bb0615","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0620","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0625","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0630","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0635","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0640","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0645","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.leu.2404481","article-title":"Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98\u20133936","volume":"21","author":"Br\u00fcggemann","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds643_bb0650","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0655","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2009.019133","article-title":"A novel subset of T-helper cells: follicular T-helper cells and their markers","volume":"95","author":"Laurent","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0660","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2559.2011.03981.x","article-title":"Peripheral T-cell lymphomas with follicular T-helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive","volume":"59","author":"Agostinelli","year":"2011","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mds643_bb0665","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0670","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","article-title":"Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas","volume":"25","author":"Cuadros","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mds643_bb0675","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3452.3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracyclines-based regimens: a comprehensive meta-analysis [Abstract]","volume":"110","author":"Abouyabis","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0680","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (TCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"25","key":"10.1093\/annonc\/mds643_bb0685","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell natural killer\/T-cell lymphoma study: pathology findings and clinical outcome","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1093\/annonc\/mds643_bb0690","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0695","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0700","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdn696","article-title":"for the International Peripheral T-cell Lymphoma Project The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia\/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project","volume":"20","author":"Suzumiya","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds643_bb0705","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International peripheral T-cell lymphoma (TCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1093\/annonc\/mds643_bb0710","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 Expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Canc Res"},{"key":"10.1093\/annonc\/mds643_bb0715","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1093\/annonc\/mds643_bb0720","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mds643_bb0725","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds643_bb0730","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood.V116.21.2829.2829","article-title":"Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-cell\/NK lymphomas: a phase II trial","volume":"116","author":"Corazzelli","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0735","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mds643_bb0740","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"issue":"9","key":"10.1093\/annonc\/mds643_bb0745","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0750","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal open-label phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mds643_bb0755","first-page":"iv125","article-title":"Preliminary results from an open-label, multicenter, phase II study of bendamustine in relapsed or refractory T-cell lymphoma from the french GOELAMS group : the BENTLY trial","volume":"22","author":"Damaj","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0760","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (TCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0765","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11899-009-0031-4","article-title":"Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?","volume":"4","author":"d'Amore","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0770","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodriguez","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1093\/annonc\/mds643_bb0775","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle","volume":"107","author":"Dhedin","year":"1999","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1093\/annonc\/mds643_bb0780","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1093\/annonc\/mds643_bb0785","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mds643_bb0790","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas (TCL): long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"10.1093\/annonc\/mds643_bb0795","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mds643_bb0800","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials","volume":"46","author":"Choi","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0805","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1093\/annonc\/mds643_bb0810","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds643_bb0815","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds643_bb0820","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428190600961058","article-title":"Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901","volume":"48","author":"Czuczman","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds643_bb0825","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapse or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"D'Amore","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1093\/annonc\/mds643_bb0830","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1093\/annonc\/mds643_bb0835","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds643_bb0840","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms or resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds643_bb0845","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.961.961","article-title":"Complete remissions with brentuximab vedotin (SGN-35) in patients with relapse or refractory systemic anaplastic large cell lymphoma","volume":"116","author":"Shustov","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mds643_bb0850","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","article-title":"Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Fanin","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1093\/annonc\/mds643_bb0855","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mds643_bb0860","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1093\/annonc\/mds643_bb0865","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds643_bb0870","first-page":"1372","article-title":"High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Haematologica"},{"issue":"11","key":"10.1093\/annonc\/mds643_bb0875","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1093\/annonc\/mds643_bb0880","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1093\/annonc\/mds643_bb0885","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mds643_bb0890","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1093\/annonc\/mds643_bb0895","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1093\/annonc\/mds643_bb0900","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","article-title":"Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen","volume":"40","author":"Smith","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/4\/857\/13789319\/mds643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:39:20Z","timestamp":1624693160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419372114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":179,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0923753419372114"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds643","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}